+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05460793

Dutch ICH Surgery Trial Minimally Invasive Endoscopy-guided Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage

Led by Radboud University Medical Center · Updated on 2024-11-21

600

Participants Needed

11

Research Sites

52 weeks

Total Duration

On this page

Sponsors

R

Radboud University Medical Center

Lead Sponsor

Z

ZonMw: The Netherlands Organisation for Health Research and Development

Collaborating Sponsor

AI-Summary

What this Trial Is About

Intracerebral hemorrhage ICH, a type of stroke causing significant death and disability, is being studied to see if early minimally invasive endoscopy-guided surgery improves patient outcomes compared to standard medical care. This trial focuses on adults with spontaneous supratentorial ICH, aiming to begin surgery within 8 hours of symptom onset. The study is a multicenter, randomized clinical trial led by Radboud University Medical Center, investigating both functional recovery and biological changes after treatment. Participants are randomly assigned to receive either minimally invasive endoscopy-guided surgery plus standard medical management or standard medical management alone. The surgical procedure uses neuronavigation-integrated devices approved for this purpose. Surgery must start within 8 hours of symptoms, and the trial includes detailed monitoring of brain imaging and immune profiles in a subgroup. The standard care group receives blood pressure management, stroke unit admission, and supportive care. Participants will be followed for up to one year with assessments at 6 days, 90 days, 180 days, and 365 days including functional scales like the modified Rankin Scale, stroke severity scores, quality of life questionnaires, and safety monitoring for complications or death. Imaging studies at baseline, 24 hours, and day 6 assess clot and edema changes. The trial also evaluates cost-effectiveness of the surgical approach. Overall participation spans up to one year with multiple clinical and imaging evaluations.

CONDITIONS

Brief Title

Dutch Intracerebral Hemorrhage Surgery Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • NIH Stroke Scale score of 2 or higher
  • Diagnosed with spontaneous supratentorial intracerebral hemorrhage confirmed by CT scan
  • No vascular abnormalities or known lesions causing the hemorrhage (aneurysm, AVM, DAVF, CVST, tumor, cavernoma)
  • Hematoma volume of at least 10 mL
  • Able to start treatment within 8 hours of symptom onset
  • Provided written informed consent (deferred consent allowed)
Not Eligible

You will not qualify if you...

  • Significant dependency before stroke, defined as modified Rankin Scale 3 or higher
  • ICH Grading Scale score of 11 or higher
  • Hemorrhage caused by transformation of an infarct
  • Untreated blood clotting problems (INR greater than 1.3) or current use of certain blood thinners unless reversed
  • Critically ill or rapidly worsening condition with expected imminent death
  • Pregnancy
  • Use of immunosuppressive or immune-modulating medication for the DIST-INFLAME sub-study participants only (200 patients)

Research Team

C

Catharina JM Klijn, MD PhD

F

Floor NH Wilting, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here